Abiopharma

🔍 Wray Michael (Executive)

Company: NWPX Infrastructure, Inc. (NWPX)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Sold 4,500 shares of Common Stock at $110.9413 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 23,886.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Sold 600 shares of Common Stock (Direct)
  Date: 2026-08-27 | Code: G | equity_swap_involved: 0 | shares_owned_after: 23,286.00 | transaction_form_type: 4 | Footnotes: F7, F7
• Holds 3,791 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: H | shares_owned_after: 3,791.00 | Footnotes: F3, F4, F4, F3
• Holds 11,368 shares of Performance Shares (Derivative)
  Date: 2026-08-26 | Code: H | shares_owned_after: 11,368.00 | Footnotes: F6, F5, F5, F6

Footnotes:

• F1: Adoption date of referenced 10b5-1(c) plan is: 05/27/2026
• F2: This transaction was executed in multiple trades at prices ranging from $109.6300 to $112.0300 per share. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Each Restricted Stock Unit represents a contingent right to receive one share of NWPX common stock.
• F4: The Restricted Stock Units vest in installments in January of 2027, 2028 and 2029.
• F5: The Performance Shares vest in installments in March of 2027, 2028 and 2029.
• F6: Performance Shares vest in an amount ranging from 0-200% to the extent such Performance Shares are earned. Performance Shares are earned based on NWPX's total EBITDA margin over the measurement period.
• F7: 600 shares represents a bona fide gift of NWPX Infrastructure, Inc. common stock made by the reporting person.